Event Participants
Executives
3 Dhiren Gala, Narashima Raju, Suprita Reddy
Analysts
9 Abin Benny, AbdulKader Puranwala, Alankar Garude, Amey Chalke, Anshul Agrawal, Bharat Sheth, Jyothish Vijayan, Kartick Bane, Siddharth K.
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue (Consolidated) | ₹98 crore | +22.8% YoY, driven by 16.5% volume growth, test mix improvement, and higher realization |
| Test Volume Growth | +16.5% YoY | Primary growth driver; balance from price/realization improvement |
| pH (Patient Footfall) Growth | +18% YoY | Driven by network expansion |
| EBITDA | ₹98 crore | +34% YoY from ₹74 crore; margin improved 360 bps YoY |
| EBITDA Margin | 42.7% | Operating leverage from existing clusters offset drag (~0.5%) from new hubs |
| PAT | ₹53 crore | +37.6% YoY |
| B2C Revenue Share | 92% | Reflects B2C-focused integrated business model |
| Radiology Revenue Share | 37% | Both radiology and pathology drove growth |
| Revenue Per Test | ₹503 | |
| Revenue Per Footfall | ₹1,860 | Higher than standalone pathology players (~₹900-950/day) |
| Tests Per Footfall | 3.7 | vs. 2.5-3 for typical pathology chains |
| Cash Position | ~₹330 crore surplus | No debt; strong balance sheet |
| Cash Conversion | 26-27% | Consistent cash generation |
| Total Centers | 166 | 51 hubs, 115 spokes, ~26 processing units |
Geographic & Segment Commentary
Hyderabad: Grew 17% YoY without incremental hub additions in recent years, contributing 67% of total revenue. This mature cluster demonstrates continued operating leverage and market leadership.
Rest of AP & Telangana: Contributed 20% of revenue, with strong performance in tier-2 locations like Rajahmundry (breakeven in month 9, ahead of plan), Tirupati, Kurnool, and Nizamabad. Wellness demand from 150-200 km catchment areas around smaller towns.
Pune: Grew 18% YoY (₹10.8 crore to ₹12.8 crore); planning a large hub with fully automated lab to address capacity constraints in existing PH centers, enabling spoke expansion and home collection.
West Bengal: Contributed 4% of revenue with Krsna Nagar outperforming expectations, achieving breakeven in just two quarters.
Bengaluru/Karnataka: First Bengaluru hub (JP Nagar) commissioned in July with advanced technology (3T Omega MR, digital PET CT); two initial pilot hubs (HSR Layout, Yelahanka) broke even in year one. Karnataka being positioned as next core geography after AP/Telangana.
Company-Specific & Strategic Commentary
Network Expansion: Nine hub centers and 10-12 spokes planned over next 12 months; two hubs (Gachibowli, JP Nagar) and six spokes already commissioned. J.P. Nagar hub (₹30 crore) features first-in-Bengaluru technologies; another ~15-16 crore per hub for remaining hubs.
Capital Allocation: Total FY27 CapEx guided at ₹190-195 crore, including Panjagutta reference laboratory and ₹8-10 crore land acquisition in AP (tier-2 medical hub) — one-off deviation from leasing model after 6-7 years of site search.
Digital & AI Initiatives: AI-powered "smart reports" for lifestyle/wellness packages with patient-specific customization; organ-based radiology AI used in KUB, chest, and breast cases after validation and certification by 400+ radiologists.
Wellness Segment: Contributed 14.8% of revenue (8% pre-COVID), growing in tier-2 geographies organically without aggressive upselling. Premium packages priced ₹8,000-10,000 with ~20% max discounting; packages now span basic panels to whole-body MRI/CT screening including cardiac angio, liver elastography, and dementia screening.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| FY27 Revenue Growth | High double-digit | Q1 delivered 23%; management confident given network momentum |
| Sustainable Long-term Growth | 15%+ (3-5 years) | Based on expansion into Karnataka, Pune, West Bengal |
| EBITDA Margin | 40%+ sustainable | Even with 1-1.5% drag from future expansion; operating leverage from existing clusters |
| CapEx | ₹190-195 crore | Includes 9 hubs, 10-12 spokes, Panjagutta reference lab, AP land purchase |
| New Hub Contribution | ~6-6.5% of revenue | From FY26 commissioned hubs; pathology revenue now scaling alongside radiology |
Risks & Constraints
| Risk | Context |
|---|---|
| New Hub Ramp-Up Risk | 9 hubs planned this year; management points to staggered commissioning vs. previous year's simultaneous launches. Three to four hubs (launched 6-12 months ago) still burning cash at ~0.5% of top line, though 10 hubs collectively are breakeven. |
| Hyderabad Market Share Validity | Competitors (2nd and 3rd largest) reportedly avoiding Hyderabad due to Vijaya's market leadership; however, no third-party data confirms market share gains. |
| Land Acquisition Execution | Purchase of AP land (₹8-10 crore) is a deviation from leasing model; requires prolonged site identification and could face regulatory/titling issues. |
| Data Monetization Constraints | Company holds valuable healthcare data but cannot monetize due to unclear regulatory framework; strict privacy policy currently in place. |
| Pricing Power Limitations | No price hikes since June 2025 (only Hyderabad, select tests); growth relies on volume and mixed shift, not pricing. |
Q&A Highlights
Network Format and Counts
- Question: What is the hub/spoke breakup of 166 centers and does this include collection centers? (Siddharth K.)
- Answer: 51 hubs, 115 spokes, ~26 processing units (processing centers are within hubs). Company does not run pure collection centers; smallest locations have ECG or X-ray. PH Diagnostic's 12 collection centers have been upgraded with imaging/cardiology capabilities. (Suprita Reddy)
CapEx Details for Q1 Hubs
- Question: What was the combined CapEx for the two hubs commissioned in Q1? (Siddharth K.)
- Answer: Bengaluru (JP Nagar) hub: ₹30 crore including 3T wide-bore MRI, digital PET-CT with cardiac CT, and state-of-the-art automated lab serving as central facility. Gachibowli, Hyderabad hub: ₹9 crore with 160-slice cardiac CT and superior infrastructure. Balance 8 hubs will be ₹15-16 crore each. (Narashima Raju)
Margins Sustainability
- Question: Given elevated Q1 margins, is 40% EBITDA still the right guide? (AbdulKader Puranwala)
- Answer: Yes, comfortable with 40%+ despite expansion drag of 1-1.5%, driven by operating leverage. 60-70% of costs are fixed; hubs already at breakeven mean incremental pathology revenue (cost of consumables ~11%) flows directly to EBITDA. (Narashima Raju, Dhiren Gala, Anshul Agrawal follow-up)
Hyderabad Competitive Landscape
- Question: How do you view competitive intensity in Hyderabad? (Abin Benny)
- Answer: The second and third-largest players are deploying capital outside Hyderabad because Vijaya has majority market share there. In Visakhapatnam, Vijaya recently added spokes; no competitor is matching network expansion intensity. B2C model and superior infrastructure remain key differentiators. (Dhiren Gala)
Pune Strategy
- Question: How has Pune performed vs. initial acquisition expectations, and is strategy being re-evaluated? (Alankar Garude)
- Answer: Pune grew 18% in Q1; strategy differs from other geographies — requires a fully automated lab for backend capacity before expanding spokes and wellness. A large hub coming this year will enable growth; one spoke added in Kharadi in July. Approach for Pune will be differentiated but growth momentum will continue. (Suprita Reddy)
Margins vs. Standalone Pathology
- Question: Why do margins expand while pathology share increases, when standalone pathologists run at lower margins? (Amey Chalke)
- Answer: Peer pathology chains have 25-30% B2B revenue at discounted prices; Vijaya's 92% B2C mix commands premium pricing. Integrated model drives 3.7 tests/footfall vs. 2.5-3 for pathology-only chains, and revenue/footfall of ₹1,860 vs. ₹900-950 for peer pathology chains. (Narashima Raju)
Wellness Segment & Bengaluru Ramp-up
- Question: How is wellness growing — corporate vs. retail, and acceptance of AI-based reports? (Abin Benny, Bharat Sheth)
- Answer: Mix of retail and corporate demand; lifestyle packages (cardiac, liver) strongest, particularly in tier-2 cities which surprised management. AI smart reports are customized to patient history/age; all lifestyle packages include these digitally. Not positioning for aggressive upselling; organic acceptance from awareness building. (Suprita Reddy, Dhiren Gala)
Key Takeaway
Vijaya Diagnostic delivered a robust Q1 FY27 with revenue growth of 22.8% YoY (volume +16.5%), EBITDA margin expanding 360 bps to 42.7%, and PAT growing 37.6% to ₹53 crore. The company is aggressively scaling its hub-and-spoke model, with nine hubs and 10-12 spokes planned (₹190-195 crore CapEx), including entry into Bengaluru with first-of-its-kind technology (3T Omega MR, digital PET-CT) and a land acquisition in AP marking a strategic one-off deviation from leasing. Management affirmed confidence in sustaining 40%+ EBITDA margins despite expansion drag, driven by operating leverage from mature clusters and high B2C mix (92%). Wellness (14.8% of revenue) is a growing structural driver. With Hyderabad growing 17% on a mature base, management guides high double-digit FY27 growth and 15%+ sustainable long-term growth, while investors should monitor new hub drag, pricing power absence, and execution pace across three new metro markets.